Townsquare Capital LLC Acquires 109,217 Shares of Haleon plc (NYSE:HLN)

Townsquare Capital LLC grew its position in Haleon plc (NYSE:HLN - Free Report) by 29.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 475,618 shares of the company's stock after purchasing an additional 109,217 shares during the period. Townsquare Capital LLC's holdings in Haleon were worth $5,032,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fortitude Family Office LLC acquired a new stake in Haleon during the 3rd quarter worth approximately $28,000. Cultivar Capital Inc. acquired a new stake in shares of Haleon during the second quarter worth $40,000. Prospera Private Wealth LLC bought a new stake in Haleon in the 3rd quarter valued at $57,000. Hexagon Capital Partners LLC boosted its stake in Haleon by 66.6% in the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company's stock worth $55,000 after purchasing an additional 2,677 shares during the period. Finally, BOKF NA increased its holdings in Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company's stock worth $58,000 after purchasing an additional 2,842 shares in the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Stock Down 0.7 %

HLN traded down $0.07 during trading on Friday, reaching $9.66. 2,989,940 shares of the stock were exchanged, compared to its average volume of 5,304,791. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock's 50 day moving average price is $9.94 and its two-hundred day moving average price is $9.41. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The stock has a market cap of $43.71 billion, a P/E ratio of 28.59, a price-to-earnings-growth ratio of 2.94 and a beta of 0.30.

Analyst Ratings Changes

A number of analysts have recently commented on HLN shares. UBS Group upgraded Haleon to a "strong-buy" rating in a report on Tuesday, October 1st. Berenberg Bank assumed coverage on shares of Haleon in a research note on Tuesday, August 6th. They set a "buy" rating for the company. The Goldman Sachs Group lowered shares of Haleon from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. Finally, Morgan Stanley raised their target price on shares of Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a research report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.